gastric cancer
Conditions
Interventions
Experimental group:Xinjia Liangfu Jianpi Yiqi Hefang Granules for oral administration
Sponsors
Dongzhimen Hospital Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Experimental group: 1) Meets the Western diagnostic criteria for advanced gastric cancer; 2) Meets the traditional Chinese medicine syndrome differentiation criteria of spleen and stomach weakness qi stagnation and blood stasis; 3) The patient has completed first-line treatment and the efficacy evaluation is complete remission partial remission or disease stability. They are about to enter the maintenance treatment stage and do not tolerate or accept Western medicine maintenance treatment including patients who have interrupted Western medicine maintenance treatment Between the ages of 18 and 80 both males and females are eligible Expected survival period is over 6 months; 6) Karnofsky score = 60 points; 7) Not participating in other clinical practices for the purpose of observing clinical efficacy; Control group: 1) Meets the Western diagnostic criteria for advanced gastric cancer; 2) The patient has completed first-line treatment and the efficacy evaluation is complete remission partial remission or disease stabil
Exclusion criteria
Exclusion criteria: Those who do not meet the inclusion criteria or although they meet the inclusion criteria have one of the following conditions as exclusion criteria: 1) those who also have primary heart brain liver kidney and hematopoietic system diseases or have serious tumor complications and comorbidities; 2) Pregnant and lactating women; 3) Individuals with allergies or known allergies to certain medications in the prescription; 4) Existence of mental illness or cognitive impairment; 5) Those who cannot take medication on time have poor compliance or cannot adhere to follow-up; 6) Merge with other primary malignant tumors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Control Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Scoring of Symptoms and Signs of Spleen and Stomach Weakness Qi Stagnation and Blood Stasis Syndrome;Lymphocyte subpopulation count;MD Anderson Symptom Inventory;Quality of Life Questionnaire of Stomach Cancer;Chinese version of the Brief Fatigue Inventory;Changes in cytokine levels;Progression free survival; | — |
Countries
China
Contacts
Public ContactLi Hou
Dongzhimen Hospital Beijing University of Chinese Medicine
Outcome results
None listed